273 related articles for article (PubMed ID: 34911927)
1. Small molecule splicing modifiers with systemic HTT-lowering activity.
Bhattacharyya A; Trotta CR; Narasimhan J; Wiedinger KJ; Li W; Effenberger KA; Woll MG; Jani MB; Risher N; Yeh S; Cheng Y; Sydorenko N; Moon YC; Karp GM; Weetall M; Dakka A; Gabbeta V; Naryshkin NA; Graci JD; Tripodi T; Southwell A; Hayden M; Colacino JM; Peltz SW
Nat Commun; 2021 Dec; 12(1):7299. PubMed ID: 34911927
[TBL] [Abstract][Full Text] [Related]
2. An orally available, brain penetrant, small molecule lowers huntingtin levels by enhancing pseudoexon inclusion.
Keller CG; Shin Y; Monteys AM; Renaud N; Beibel M; Teider N; Peters T; Faller T; St-Cyr S; Knehr J; Roma G; Reyes A; Hild M; Lukashev D; Theil D; Dales N; Cha JH; Borowsky B; Dolmetsch R; Davidson BL; Sivasankaran R
Nat Commun; 2022 Mar; 13(1):1150. PubMed ID: 35241644
[TBL] [Abstract][Full Text] [Related]
3. Reducing Mutant Huntingtin Protein Expression in Living Cells by a Newly Identified RNA CAG Binder.
Matthes F; Massari S; Bochicchio A; Schorpp K; Schilling J; Weber S; Offermann N; Desantis J; Wanker E; Carloni P; Hadian K; Tabarrini O; Rossetti G; Krauss S
ACS Chem Neurosci; 2018 Jun; 9(6):1399-1408. PubMed ID: 29506378
[TBL] [Abstract][Full Text] [Related]
4. Myricetin Reduces Toxic Level of CAG Repeats RNA in Huntington's Disease (HD) and Spino Cerebellar Ataxia (SCAs).
Khan E; Tawani A; Mishra SK; Verma AK; Upadhyay A; Kumar M; Sandhir R; Mishra A; Kumar A
ACS Chem Biol; 2018 Jan; 13(1):180-188. PubMed ID: 29172480
[TBL] [Abstract][Full Text] [Related]
5. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease.
Caron NS; Southwell AL; Brouwers CC; Cengio LD; Xie Y; Black HF; Anderson LM; Ko S; Zhu X; van Deventer SJ; Evers MM; Konstantinova P; Hayden MR
Nucleic Acids Res; 2020 Jan; 48(1):36-54. PubMed ID: 31745548
[TBL] [Abstract][Full Text] [Related]
6. Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.
Zhou X; Li G; Kaplan A; Gaschler MM; Zhang X; Hou Z; Jiang M; Zott R; Cremers S; Stockwell BR; Duan W
Hum Mol Genet; 2018 May; 27(9):1545-1555. PubMed ID: 29462355
[TBL] [Abstract][Full Text] [Related]
7. Systemic delivery of mutant huntingtin lowering antisense oligonucleotides to the brain using apolipoprotein A-I nanodisks for Huntington disease.
Caron NS; Aly AE; Findlay Black H; Martin DDO; Schmidt ME; Ko S; Anderson C; Harvey EM; Casal LL; Anderson LM; Rahavi SMR; Reid GSD; Oda MN; Stanimirovic D; Abulrob A; McBride JL; Leavitt BR; Hayden MR
J Control Release; 2024 Mar; 367():27-44. PubMed ID: 38215984
[TBL] [Abstract][Full Text] [Related]
8. AAV5-miHTT Gene Therapy Demonstrates Broad Distribution and Strong Human Mutant Huntingtin Lowering in a Huntington's Disease Minipig Model.
Evers MM; Miniarikova J; Juhas S; Vallès A; Bohuslavova B; Juhasova J; Skalnikova HK; Vodicka P; Valekova I; Brouwers C; Blits B; Lubelski J; Kovarova H; Ellederova Z; van Deventer SJ; Petry H; Motlik J; Konstantinova P
Mol Ther; 2018 Sep; 26(9):2163-2177. PubMed ID: 30007561
[TBL] [Abstract][Full Text] [Related]
9. Cancer: From Wild-Type to Mutant Huntingtin.
Thion MS; Humbert S
J Huntingtons Dis; 2018; 7(3):201-208. PubMed ID: 29889077
[TBL] [Abstract][Full Text] [Related]
10. Identification and Optimization of RNA-Splicing Modulators as Huntingtin Protein-Lowering Agents for the Treatment of Huntington's Disease.
Liu L; Malagu K; Haughan AF; Khetarpal V; Stott AJ; Esmieu W; Vater HD; Webster SJ; Van de Poël AJ; Clissold C; Cosgrove B; Sutton B; Spencer JA; Breccia P; Gancia E; Bonomo S; Ladduwahetty T; Lazari O; Patel H; Atton HC; Clifton S; Mota DM; Magnani D; O'Neill A; Stebbeds M; Macabuag N; Todd D; Herva ME; Mitchell P; Visser M; Compte Sancerni S; Grand Moursel L; da Silva M; Kritikou E; Heikkinen TT; Bolkvadze T; Fodale V; Spadafora D; Daldin M; Bresciani A; Mangette JE; Doherty EM; Lee MR; Herbst T; Monteagudo E; Macdonald D; Plotnikov NV; Chambers M; McAllister G; Muňoz-Sanjuan I; Dominguez C
J Med Chem; 2023 Sep; 66(18):13205-13246. PubMed ID: 37712656
[TBL] [Abstract][Full Text] [Related]
11. Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington's Disease.
Imbert M; Blandel F; Leumann C; Garcia L; Goyenvalle A
Nucleic Acid Ther; 2019 Oct; 29(5):256-265. PubMed ID: 31184975
[TBL] [Abstract][Full Text] [Related]
12. Phenotype onset in Huntington's disease knock-in mice is correlated with the incomplete splicing of the mutant huntingtin gene.
Franich NR; Hickey MA; Zhu C; Osborne GF; Ali N; Chu T; Bove NH; Lemesre V; Lerner RP; Zeitlin SO; Howland D; Neueder A; Landles C; Bates GP; Chesselet MF
J Neurosci Res; 2019 Dec; 97(12):1590-1605. PubMed ID: 31282030
[TBL] [Abstract][Full Text] [Related]
13. Analysis of mutant and total huntingtin expression in Huntington's disease murine models.
Fodale V; Pintauro R; Daldin M; Altobelli R; Spiezia MC; Bisbocci M; Macdonald D; Bresciani A
Sci Rep; 2020 Dec; 10(1):22137. PubMed ID: 33335120
[TBL] [Abstract][Full Text] [Related]
14. A high-throughput screening to identify small molecules that suppress huntingtin promoter activity or activate huntingtin-antisense promoter activity.
Khaled HG; Feng H; Hu X; Sun X; Zheng W; Li PP; Rudnicki DD; Ye W; Chen YC; Southall N; Marugan J; Ross CA; Ferrer M; Henderson MJ; Margolis RL
Sci Rep; 2021 Mar; 11(1):6157. PubMed ID: 33731741
[TBL] [Abstract][Full Text] [Related]
15. A Fresh Look at Huntingtin mRNA Processing in Huntington's Disease.
Romo L; Mohn ES; Aronin N
J Huntingtons Dis; 2018; 7(2):101-108. PubMed ID: 29865084
[TBL] [Abstract][Full Text] [Related]
16. Targeting CAG repeat RNAs reduces Huntington's disease phenotype independently of huntingtin levels.
Rué L; Bañez-Coronel M; Creus-Muncunill J; Giralt A; Alcalá-Vida R; Mentxaka G; Kagerbauer B; Zomeño-Abellán MT; Aranda Z; Venturi V; Pérez-Navarro E; Estivill X; Martí E
J Clin Invest; 2016 Nov; 126(11):4319-4330. PubMed ID: 27721240
[TBL] [Abstract][Full Text] [Related]
17. Lowering mutant huntingtin by small molecules relieves Huntington's disease symptoms and progression.
Bahat A; Itzhaki E; Weiss B; Tolmasov M; Tsoory M; Kuperman Y; Brandis A; Shurrush KA; Dikstein R
EMBO Mol Med; 2024 Mar; 16(3):523-546. PubMed ID: 38374466
[TBL] [Abstract][Full Text] [Related]
18. An alternative splicing modulator decreases mutant HTT and improves the molecular fingerprint in Huntington's disease patient neurons.
Krach F; Stemick J; Boerstler T; Weiss A; Lingos I; Reischl S; Meixner H; Ploetz S; Farrell M; Hehr U; Kohl Z; Winner B; Winkler J
Nat Commun; 2022 Nov; 13(1):6797. PubMed ID: 36357392
[TBL] [Abstract][Full Text] [Related]
19. Increased Steady-State Mutant Huntingtin mRNA in Huntington's Disease Brain.
Liu W; Chaurette J; Pfister EL; Kennington LA; Chase KO; Bullock J; Vonsattel JP; Faull RL; Macdonald D; DiFiglia M; Zamore PD; Aronin N
J Huntingtons Dis; 2013; 2(4):491-500. PubMed ID: 25062733
[TBL] [Abstract][Full Text] [Related]
20. An RNA-targeting CRISPR-Cas13d system alleviates disease-related phenotypes in Huntington's disease models.
Morelli KH; Wu Q; Gosztyla ML; Liu H; Yao M; Zhang C; Chen J; Marina RJ; Lee K; Jones KL; Huang MY; Li A; Smith-Geater C; Thompson LM; Duan W; Yeo GW
Nat Neurosci; 2023 Jan; 26(1):27-38. PubMed ID: 36510111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
